PL2623498T3 - Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu - Google Patents

Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu

Info

Publication number
PL2623498T3
PL2623498T3 PL11829253T PL11829253T PL2623498T3 PL 2623498 T3 PL2623498 T3 PL 2623498T3 PL 11829253 T PL11829253 T PL 11829253T PL 11829253 T PL11829253 T PL 11829253T PL 2623498 T3 PL2623498 T3 PL 2623498T3
Authority
PL
Poland
Prior art keywords
fluoro
hydroxy
sodium salt
pyrazine carboxamide
pyrazine
Prior art date
Application number
PL11829253T
Other languages
English (en)
Inventor
Keiko Takakura
Namika Nakamatsu
Sakiko Takeshima
Sayuri Uehara
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PL2623498T3 publication Critical patent/PL2623498T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
PL11829253T 2010-09-30 2011-09-29 Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu PL2623498T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010221682 2010-09-30
PCT/JP2011/072333 WO2012043700A1 (ja) 2010-09-30 2011-09-29 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのナトリウム塩
EP11829253.1A EP2623498B1 (en) 2010-09-30 2011-09-29 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide

Publications (1)

Publication Number Publication Date
PL2623498T3 true PL2623498T3 (pl) 2016-05-31

Family

ID=45893139

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11829253T PL2623498T3 (pl) 2010-09-30 2011-09-29 Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu

Country Status (19)

Country Link
US (3) US20130274472A1 (pl)
EP (1) EP2623498B1 (pl)
JP (1) JPWO2012043700A1 (pl)
CN (1) CN103209966B (pl)
CY (1) CY1117041T1 (pl)
DK (1) DK2623498T3 (pl)
ES (1) ES2554630T3 (pl)
HR (1) HRP20151263T1 (pl)
HU (1) HUE026872T2 (pl)
MY (1) MY161429A (pl)
PH (2) PH12013500604A1 (pl)
PL (1) PL2623498T3 (pl)
PT (1) PT2623498E (pl)
RS (1) RS54408B1 (pl)
SG (1) SG189161A1 (pl)
SI (1) SI2623498T1 (pl)
SM (1) SMT201600072B (pl)
TW (1) TWI552998B (pl)
WO (1) WO2012043700A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US20130217708A1 (en) * 2010-09-30 2013-08-22 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EP2937348B1 (en) * 2012-12-22 2021-09-08 Kbp Biosciences Pte. Ltd. Process for the preparation of a compound used as mineralocorticoid receptor antagonist
WO2016108534A1 (ko) * 2014-12-30 2016-07-07 주식회사 삼양바이오팜 고분자 나노입자 동결건조물 및 그 제조방법
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
TW201808291A (zh) * 2016-06-30 2018-03-16 富山化學工業股份有限公司 冷凍乾燥製劑之製造方法
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11679083B2 (en) * 2017-12-28 2023-06-20 Fujifilm Toyama Chemical Co., Ltd. Method for producing freeze-dried formulation
WO2020106735A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN111249229B (zh) * 2020-03-10 2023-05-02 北京阜康仁生物制药科技有限公司 一种稳定的法匹拉韦注射液及其制备方法
CN114075145A (zh) * 2020-08-14 2022-02-22 广东东阳光药业有限公司 一种法匹拉韦盐及其晶型和制备方法
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
TR202017792A2 (tr) * 2020-11-06 2021-01-21 Aroma Ilac Sanayi Ltd Sti 6-floro-3-hidroksi-2-pirazinkarboksamid etken maddesi veya sodyum tuzunu içeren liyofilizasyon tekniğiyle üretilen yeni bir farmasötik kompozisyon
CN113750105A (zh) * 2020-12-11 2021-12-07 山东大学 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用
CN112574130B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药物共晶及其制备方法和应用
JPWO2022131112A1 (pl) * 2020-12-18 2022-06-23
CN116761591A (zh) * 2020-12-18 2023-09-15 富士胶片富山化学株式会社 药物组合物
WO2023033683A1 (ru) * 2021-09-06 2023-03-09 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736555B2 (en) 1998-01-07 2001-08-02 Meiji Seika Pharma Co., Ltd. A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof
ID28806A (id) 1998-08-20 2001-07-05 Toyama Chemical Co Ltd Turunan-turunan karboksamida heterosiklik yang mengandung nitrogen atau garam-garam daripadanya dan zat-zat antivirus yang terdiri dari senyawa ini
KR100604955B1 (ko) 2000-02-16 2006-07-26 토야마 케미칼 컴퍼니 리미티드 신규한 피라진 유도체 또는 그 염, 이를 함유하는 의약조성물, 및 그 제조 중간물
BRPI0807597B8 (pt) * 2007-02-16 2021-05-25 Fujifilm Toyama Chemical Co Ltd composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
JP2008231064A (ja) 2007-03-23 2008-10-02 Nippon Shokubai Co Ltd カルバゾイルアルキル(メタ)アクリレートの製造方法
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2192117B1 (en) * 2007-09-27 2014-06-04 Toyama Chemical Co., Ltd. Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same
TWI463999B (zh) 2009-03-13 2014-12-11 Toyama Chemical Co Ltd 含有6-氟-3-羥基-2-吡羧醯胺之錠劑及粒狀粉末
US20130217708A1 (en) 2010-09-30 2013-08-22 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide

Also Published As

Publication number Publication date
EP2623498A4 (en) 2014-03-26
CY1117041T1 (el) 2017-04-05
US20130274472A1 (en) 2013-10-17
JPWO2012043700A1 (ja) 2014-02-24
PT2623498E (pt) 2016-02-02
WO2012043700A1 (ja) 2012-04-05
HK1183015A1 (en) 2013-12-13
US20150038713A1 (en) 2015-02-05
SMT201600072B (it) 2016-04-29
CN103209966A (zh) 2013-07-17
HUE026872T2 (en) 2016-07-28
ES2554630T3 (es) 2015-12-22
US9096547B2 (en) 2015-08-04
HRP20151263T1 (hr) 2015-12-18
PH12013500604A1 (en) 2013-05-06
SG189161A1 (en) 2013-05-31
DK2623498T3 (en) 2016-02-22
CN103209966B (zh) 2015-06-10
TWI552998B (zh) 2016-10-11
SI2623498T1 (sl) 2016-03-31
TW201219375A (en) 2012-05-16
PH12015501649A1 (en) 2015-10-05
PH12015501649B1 (en) 2015-10-05
RS54408B1 (sr) 2016-04-28
MY161429A (en) 2017-04-14
EP2623498B1 (en) 2015-11-18
US20150266831A1 (en) 2015-09-24
EP2623498A1 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
SI2623498T1 (sl) Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
PL2623497T3 (pl) Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu
PL2742051T3 (pl) Amorficzna postać soli sodowej dolutegrawiru
HUE055375T2 (hu) Fluorszulfonil-imid alkálifémsója
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
IL232599A (en) Hydrobromide salt of peridofidine
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
ZA201503331B (en) Inhibitors of sodium glucose cotransporter 1
ZA201209407B (en) Modification of xylan
GB201003274D0 (en) Methods of connecting
ZA201302476B (en) Aluminum salt containing high percentage of al30
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
GB0906379D0 (en) Reduced sodium salt
IL316296A (en) Polymorphic forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxypyridine-4-carbonyl)-phenyl]-benzenesulfonamide
PT2542591T (pt) Derivados silílicos de polissacáridos
ZA201205320B (en) Preparation process of the sodium salt of esomeprazole
EP2593096A4 (en) DICLOFENAC SALT OF TRAMADOL
EP2688426A4 (en) SALT COMPOSITION WITH REDUCED SODIUM CONTENT
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
TWM389379U (en) Structural improvement of connector
GB2493855B (en) Reduced sodium salt
IL243320A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
HUP1000616A2 (en) Process for preparation of rosuvastatin salt
HU1000688D0 (en) Use of trifluoro-phal
GB201216287D0 (en) Reduced sodium salt